Stoke Therapeutics, Inc.
STOK
$9.76
-$0.12-1.22%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 707.07% | 47.94% | 294.72% | -18.17% | -14.26% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 707.07% | 47.94% | 294.72% | -18.17% | -14.26% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 707.07% | 47.94% | 294.72% | -18.17% | -14.26% |
| SG&A Expenses | 21.06% | 23.57% | 27.44% | 0.09% | 13.06% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.98% | 14.26% | 11.02% | 9.20% | 6.39% |
| Operating Income | 53.85% | -10.17% | 11.79% | -14.91% | -8.87% |
| Income Before Tax | 61.12% | -7.69% | 16.18% | -16.98% | -5.08% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 61.12% | -7.69% | 16.18% | -16.98% | -5.08% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 61.12% | -7.69% | 16.18% | -16.98% | -5.08% |
| EBIT | 53.85% | -10.17% | 11.79% | -14.91% | -8.87% |
| EBITDA | 54.68% | -10.78% | 11.81% | -15.42% | -9.01% |
| EPS Basic | 69.35% | 15.39% | 33.57% | -7.60% | 7.84% |
| Normalized Basic EPS | 69.34% | 15.38% | 33.58% | -7.58% | 7.82% |
| EPS Diluted | 69.35% | 15.39% | 33.57% | -7.60% | 7.84% |
| Normalized Diluted EPS | 69.34% | 15.38% | 33.58% | -7.58% | 7.82% |
| Average Basic Shares Outstanding | 26.85% | 27.28% | 26.20% | 8.72% | 14.01% |
| Average Diluted Shares Outstanding | 26.85% | 27.28% | 26.20% | 8.72% | 14.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |